PURPOSE: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. PATIENTS AND METHODS: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m(2) on days 1 through 4 and gemcitabine 1,000 mg/m(2) on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. RESULTS: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. CONCLUSION: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.
PURPOSE:Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. PATIENTS AND METHODS: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m(2) on days 1 through 4 and gemcitabine 1,000 mg/m(2) on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. RESULTS: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. CONCLUSION: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.
Authors: N Liu; J E Lamerdin; R S Tebbs; D Schild; J D Tucker; M R Shen; K W Brookman; M J Siciliano; C A Walter; W Fan; L S Narayana; Z Q Zhou; A W Adamson; K J Sorensen; D J Chen; N J Jones; L H Thompson Journal: Mol Cell Date: 1998-05 Impact factor: 17.970
Authors: D K Bishop; U Ear; A Bhattacharyya; C Calderone; M Beckett; R R Weichselbaum; A Shinohara Journal: J Biol Chem Date: 1998-08-21 Impact factor: 5.157
Authors: C J van Moorsel; J R Kroep; H M Pinedo; G Veerman; D A Voorn; P E Postmus; J B Vermorken; C J van Groeningen; W J van der Vijgh; G J Peters Journal: Ann Oncol Date: 1999-04 Impact factor: 32.976
Authors: Jian Gu; Hua Zhao; Colin P Dinney; Yong Zhu; Dan Leibovici; Carlos E Bermejo; H Barton Grossman; Xifeng Wu Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: James M Allan; Alexandra G Smith; Keith Wheatley; Robert K Hills; Lois B Travis; Deirdre A Hill; David M Swirsky; Gareth J Morgan; Christopher P Wild Journal: Blood Date: 2004-08-31 Impact factor: 22.113
Authors: Fady L Nasr; George Y Chahine; Joseph G Kattan; Fadi S Farhat; Walid T Mokaddem; Elias A Tueni; Joya E Dagher; Marwan G Ghosn Journal: Clin Breast Cancer Date: 2004-06 Impact factor: 3.225
Authors: Nelson L S Tang; Chen Di Liao; Xingyan Wang; Frankie K F Mo; Vicky T C Chan; Rita Ng; Elizabeth Pang; Joyce J S Suen; Jean Woo; Winnie Yeo Journal: J Cancer Res Clin Oncol Date: 2012-11-10 Impact factor: 4.553
Authors: Ahmed Aribi; Sigal Gery; Dhong Hyun Lee; Nils H Thoennissen; Gabriela B Thoennissen; Rocio Alvarez; Quoc Ho; Kunik Lee; Ngan B Doan; Kin T Chan; Melvin Toh; Jonathan W Said; H Phillip Koeffler Journal: Int J Cancer Date: 2012-12-13 Impact factor: 7.396